Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 24, 2026 - P1/2 | N=43 | Active, not recruiting | Sponsor: Barbara Ann Karmanos Cancer Institute | Trial completion date: Dec 2027 ➔ Jun 2027 | Trial primary completion date: Dec 2027 ➔ Jun 2027
IO biomarker • Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Waldenstrom Macroglobulinemia
|